

## MEDICAL POLICY – 7.01.132

## Transcatheter Aortic-Valve Implantation for Aortic Stenosis

BCBSA Ref. Policy: 7.01.132

Effective Date: May 1, 2024

Last Revised: April 9, 2024


Replaces: 7.01.585

## RELATED MEDICAL POLICIES:

7.01.131 Transcatheter Pulmonary Valve Implantation

Select a hyperlink below to be directed to that section.

[POLICY CRITERIA](#) | [DOCUMENTATION REQUIREMENTS](#) | [CODING](#)  
[RELATED INFORMATION](#) | [EVIDENCE REVIEW](#) | [REFERENCES](#) | [HISTORY](#)

 Clicking this icon returns you to the hyperlinks menu above.

## Introduction

The aortic valve is a valve that separates the main pumping chamber of the heart (the left ventricle) from the large artery that takes oxygen rich blood away from the heart and out to the body (the aorta). If the valve doesn't completely open, it is called aortic stenosis. Aortic stenosis decreases the amount of oxygenated blood getting out to the body. Open surgery is one method of replacing a damaged aortic valve. A newer procedure — known as transcatheter aortic valve replacement or transcatheter aortic valve implantation — has been developed. It allows a replacement valve to be threaded through an artery and into the heart without open heart surgery. A catheter (a long thin, tube) is threaded through an artery, either in the leg or in the chest, and into the heart. The replacement valve is then lodged into the defective aortic valve. The new valve is then expanded, pushing aside parts of the old valve. This policy describes when transcatheter aortic valve replacement may be considered medically necessary.

**Note:** The Introduction section is for your general knowledge and is not to be taken as policy coverage criteria. The rest of the policy uses specific words and concepts familiar to medical professionals. It is intended for providers. A provider can be a person, such as a doctor, nurse, psychologist, or dentist. A provider also can be a place where medical care is given, like a hospital, clinic, or lab. This policy informs them about when a service may be covered.

## Policy Coverage Criteria

Procedure	Medical Necessity
<p><b>Transcatheter aortic valve replacement</b></p>	<p><b>Transcatheter aortic valve replacement with an FDA–approved transcatheter heart valve system, performed via an approach consistent with the device’s FDA-approved labeling, may be considered medically necessary for individuals with native valve aortic stenosis when ALL of the following conditions are present:</b></p> <ul style="list-style-type: none"> <li>• Severe aortic stenosis (see the <b>Definition of Terms</b> section) with a calcified aortic valve</li> </ul> <p><b>AND</b></p> <ul style="list-style-type: none"> <li>• New York Heart Association (NYHA) heart failure class II, III, or IV symptoms (see the <b>Definition of Terms</b> section)</li> </ul> <p><b>AND</b></p> <ul style="list-style-type: none"> <li>• Individual does not have unicuspid or bicuspid aortic valves</li> </ul> <p><b>Transcatheter aortic valve replacement with a transcatheter heart valve system approved for use for repair of a degenerated bioprosthetic valve (valve-in-valve) may be considered medically necessary when ALL of the following conditions are present:</b></p> <ul style="list-style-type: none"> <li>• Failure (stenosed, insufficient, or combined) of a surgical bioprosthetic aortic valve</li> </ul> <p><b>AND</b></p> <ul style="list-style-type: none"> <li>• New York Heart Association heart failure class II, III, or IV symptoms (see the <b>Definition of Terms</b> section)</li> </ul> <p><b>AND</b></p> <ul style="list-style-type: none"> <li>• Individual is not an operable candidate for open surgery, as documented by at least 2 cardiovascular specialists (including a cardiac surgeon)</li> </ul> <p><b>OR</b></p> <ul style="list-style-type: none"> <li>• Individual is an operable candidate but is considered at increased surgical risk for open surgery, as documented by at least 2 cardiac specialists (including a cardiac surgeon)</li> </ul> <p><b>OR</b></p>



Procedure	Medical Necessity
	<ul style="list-style-type: none"> <li>Individual is considered at increased surgical risk for open surgery (e.g., repeat sternotomy) due to a history of congenital vascular anomalies <b>and/or</b> has a complex intrathoracic surgical history, as documented by at least 2 cardiovascular specialists (including a cardiac surgeon) (see the <a href="#">Definition of Terms</a> section)</li> </ul> <p><b>Transcatheter aortic valve replacement is considered investigational for all other indications and when above criteria are not met.</b></p>

Procedure	Investigational
<b>Cerebral embolic protection devices</b>	<b>Use of a cerebral embolic protection device (e.g., Sentinel) during transcatheter aortic valve replacement procedures is considered investigational</b>

Documentation Requirements
<p><b>The individual’s medical records submitted for review should document that medical necessity criteria are met. The record should include clinical documentation of:</b></p> <ul style="list-style-type: none"> <li>Diagnosis/condition</li> <li>History and physical examination documenting the severity of the condition</li> <li>NYHA heart failure class symptoms</li> <li>Individual is at high risk for open surgery or is not an operable candidate for open surgery (see <a href="#">Definition of Terms</a> below)</li> <li>Whether transcatheter heart valve system is FDA approved and will be used in a manner consistent with FDA labeling</li> </ul>

## Coding

Code	Description
<b>CPT</b>	
33361	Transcatheter aortic valve replacement (TAVR/TAVI) with prosthetic valve; percutaneous femoral artery approach



Code	Description
33362	Transcatheter aortic valve replacement (TAVR/TAVI) with prosthetic valve; open femoral artery approach
33363	Transcatheter aortic valve replacement (TAVR/TAVI) with prosthetic valve; open axillary artery approach
33364	Transcatheter aortic valve replacement (TAVR/TAVI) with prosthetic valve; open iliac artery approach
33365	Transcatheter aortic valve replacement (TAVR/TAVI) with prosthetic valve; transaortic approach (e.g., median sternotomy, mediastinotomy)
33366	Transcatheter aortic valve replacement (TAVR/TAVI) with prosthetic valve; transapical exposure (e.g., left thoracotomy)
33367	Transcatheter aortic valve replacement (TAVR/TAVI) with prosthetic valve; cardiopulmonary bypass support with percutaneous peripheral arterial and venous cannulation (e.g., femoral vessels) (List separately in addition to code for primary procedure)
33368	Transcatheter aortic valve replacement (TAVR/TAVI) with prosthetic valve; cardiopulmonary bypass support with open peripheral arterial and venous cannulation (e.g., femoral, iliac, axillary vessels) (List separately in addition to code for primary procedure)
33369	Transcatheter aortic valve replacement (TAVR/TAVI) with prosthetic valve; cardiopulmonary bypass support with central arterial and venous cannulation (e.g., aorta, right atrium, pulmonary artery) (List separately in addition to code for primary procedure)
33370	Transcatheter placement and subsequent removal of cerebral embolic protection device(s), including arterial access, catheterization, imaging, and radiological supervision and interpretation, percutaneous (List separately in addition to code for primary procedure)
HCPCS	
C1884	Embolization protective system

**Note:** CPT codes, descriptions and materials are copyrighted by the American Medical Association (AMA). HCPCS codes, descriptions and materials are copyrighted by Centers for Medicare Services (CMS).

## Related Information

### Definition of Terms

**Extreme risk or inoperable for open heart surgery:** The US Food and Drug Administration (FDA) definition of extreme risk or inoperable for open surgery is:



- Predicted risk of operative mortality and/or serious irreversible morbidity 50% or higher for open surgery

**High risk for open heart surgery:** FDA definition of high risk for open surgery is:

- Society of Thoracic Surgeons predicted operative risk score of 8% or higher; or
- Judged by a heart team, which includes an experienced cardiac surgeon and a cardiologist, to have an expected mortality risk of 15% or higher for open surgery

**Intermediate risk:** FDA definition of intermediate risk is:

- Society of Thoracic Surgeons predicted operative risk score of 3% to 7%.

Individuals with Society of Thoracic Surgeons predicted operative risk score of less than 3% or 4% are considered at low risk for open surgery.

Some individuals being considered for valve-in-valve transcatheter aortic valve replacement may be deemed at increased surgical risk for open surgery despite low-to-moderate STS risk scores. This may include individuals with advanced age, complex intrathoracic histories, congenital cardiac anomalies, liver disease, or other extreme comorbid conditions not accurately captured by STS risk scores as documented by at least 2 cardiovascular specialists, including a cardiac surgeon.<sup>1,2</sup>

**Severe aortic stenosis:** For the use of the SAPIEN or CoreValve devices, severe aortic stenosis is defined by the presence of one or more of the following criteria:

- An aortic valve area of less than or equal to 1 cm<sup>2</sup>
- An aortic valve area index of less than or equal to 0.6 cm<sup>2</sup>/m<sup>2</sup>
- A mean aortic valve gradient greater than or equal to 40 mm Hg
- A peak aortic-jet velocity greater than or equal to 4.0 m/s

**New York Heart Association (NYHA) Classification:**

**Class I** No symptoms and no limitation in ordinary physical activity, e.g., shortness of breath when walking, climbing stairs etc.

**Class II** Mild symptoms (mild shortness of breath and/or angina) and slight limitation during ordinary activity.

**Class III** Marked limitation in activity due to symptoms, even during less-than-ordinary activity, e.g., walking short distances (20–100 m). Comfortable only at rest.



**Class IV** Severe limitations. Experiences symptoms even while at rest. Mostly bedbound patients

## Evidence Review

---

### Description

Aortic stenosis is narrowing of the aortic valve opening, resulting in obstruction of blood flow from the left ventricle into the ascending aorta. Individuals with untreated, symptomatic severe aortic stenosis have a poor prognosis. Valve replacement is an effective treatment for severe aortic stenosis. Transcatheter aortic valve implantation (TAVI; also known as transcatheter aortic valve replacement [TAVR]) is being evaluated as an alternative to open surgery for individuals with aortic stenosis and to nonsurgical therapy for individuals with a prohibitive risk for surgery.

### Background

#### Aortic Stenosis

Aortic stenosis is defined as narrowing of the aortic valve opening, resulting in obstruction of blood flow from the left ventricle into the ascending aorta. Progressive calcification of the aortic valve is the most common etiology in North America and Europe, while rheumatic fever is the most common etiology in developing countries.<sup>3</sup> Congenital abnormalities of the aortic valve, most commonly a bicuspid or unicuspid valve, increase the risk of aortic stenosis, but aortic stenosis can also occur in a normal aortic valve. Risk factors for calcification of a congenitally normal valve mirror those for atherosclerotic vascular disease, including advanced age, male gender, smoking, hypertension, and hyperlipidemia.<sup>3</sup> Thus, the pathogenesis of calcific aortic stenosis is thought to be similar to that of atherosclerosis (i.e., deposition of atherogenic lipids and infiltration of inflammatory cells, followed by progressive calcification).

The natural history of aortic stenosis involves a long asymptomatic period, with slowly progressive narrowing of the valve until the stenosis reaches the severe stage. At this time, symptoms of dyspnea, chest pain, and/or dizziness/syncope often occur, and the disorder progresses rapidly. Treatment of aortic stenosis is replacement of the diseased valve with a bioprosthetic or mechanical valve.



## Disease Burden

Aortic stenosis is a relatively common disorder in elderly individuals and is the most common acquired valve disorder in the United States. Approximately 2% to 4% of people older than 65 years of age have evidence of significant aortic stenosis,<sup>3</sup> increasing up to 8% of people by age 85 years.<sup>4</sup> In the Helsinki Aging Study (1993), a population-based study of 501 individuals ages 75 to 86 years, the prevalence of severe aortic stenosis by echocardiography was estimated to be 2.9%.<sup>5</sup> In the US, more than 50,000 aortic valve replacements are performed annually due to severe aortic stenosis.

Aortic stenosis does not cause substantial morbidity or mortality when the disease is mild or moderate in severity. By the time it becomes severe, there is an untreated mortality rate of approximately 50% within 2 years.<sup>6</sup> Open surgical repair is an effective treatment for reversing aortic stenosis, and artificial valves have demonstrated good durability for up to 20 years.<sup>6</sup> However, these benefits are accompanied by a perioperative mortality of approximately 3% to 4% and substantial morbidity,<sup>6</sup> both of which increase with advancing age.

## Unmet Needs

Many individuals with severe, symptomatic aortic stenosis are poor operative candidates. Approximately 30% of individuals presenting with severe aortic stenosis do not undergo open surgery due to factors such as advanced age, advanced left ventricular dysfunction, or multiple medical comorbidities.<sup>7</sup> For individuals who are not surgical candidates, medical therapy can partially alleviate the symptoms of aortic stenosis but does not affect the underlying disease progression. Percutaneous balloon valvuloplasty can be performed, but this procedure has less than optimal outcomes.<sup>8</sup> Balloon valvuloplasty can improve symptoms and increase flow across the stenotic valve but is associated with high rates of complications such as stroke, myocardial infarction, and aortic regurgitation. Also, restenosis can occur rapidly, and there is no improvement in mortality. As a result, there is a large unmet need for less invasive treatments for aortic stenosis in individuals who are at increased risk for open surgery.

## Treatment

TAVI, also known as transcatheter aortic valve replacement (TAVR), has been developed in response to this unmet need and was originally intended as an alternative for individuals for



whom surgery was not an option due to prohibitive surgical risk or for individuals at high risk for open surgery. The procedure is performed percutaneously, most often through the transfemoral artery approach. It can also be done through the subclavian artery approach and transapically using mediastinoscopy. Balloon valvuloplasty is first performed to open up the stenotic area. This is followed by passage of a bioprosthetic artificial valve across the native aortic valve. The valve is initially compressed to allow passage across the native valve and is then expanded and secured to the underlying aortic valve annulus. The procedure is performed on the beating heart without cardiopulmonary bypass.

## Summary of Evidence

For individuals who have severe symptomatic aortic stenosis who are at prohibitive risk for open surgery who receive TAVI, the evidence includes a randomized controlled trial (RCT) comparing TAVI with medical management in individuals at prohibitive risk of surgery, a single-arm prospective trial, multiple case series, and multiple systematic reviews. The relevant outcomes are overall survival (OS), symptoms, morbid events, and treatment-related mortality and morbidity. For individuals who are not surgical candidates due to excessive surgical risk, the Placement of AoRTic TraNscathetER Valve Trial Edwards SAPIEN Transcatheter Heart Valve (PARTNER B) trial reported on results for individuals treated with TAVI by the transfemoral approach compared with continued medical care with or without balloon valvuloplasty. There was a large decrease in mortality for the TAVI individuals at one year compared with medical care. This trial also reported improvements in other relevant clinical outcomes for the TAVI group. There was an increased risk of stroke and vascular complications in the TAVI group. Despite these concerns, the overall balance of benefits and risks from this trial indicate that health outcomes are improved. For individuals who are not surgical candidates, no randomized trials have compared the self-expandable valve with best medical therapy. However, results from the single-arm CoreValve Extreme Risk Pivotal Trial met trialists' pre-specified objective performance goal. The evidence is sufficient to determine that the technology results in an improvement in the net health outcome.

For individuals who have severe symptomatic aortic stenosis who are at high risk for open surgery who receive TAVI, the evidence includes two RCTs comparing TAVI with surgical repair in individuals at high risk for surgery and one RCT comparing two types of valves, multiple nonrandomized comparative studies, and systematic reviews of these studies. The relevant outcomes are OS, symptoms, morbid events, and treatment-related mortality and morbidity. For individuals who are high risk for open surgery and are surgical candidates, the PARTNER A trial reported noninferiority for survival at one year for the balloon-expandable valve compared with





open surgery. In this trial, TAVI individuals also had higher risks for stroke and vascular complications. Nonrandomized comparative studies of TAVI versus open surgery in high-risk individuals have reported no major differences in rates of mortality or stroke between the two procedures. Since the publication of the PARTNER A trial, the CoreValve High Risk Trial demonstrated noninferiority for survival at one and two years for the self-expanding prosthesis. This trial reported no significant differences in stroke rates between groups. An RCT directly comparing the Portico valve with other FDA-approved valves found an increase in safety outcomes with Portico at 30 days but no major differences at two years. Gender-specific meta-analyses have found improved mortality with TAVI compared with surgical aortic valve replacement (SAVR) in women. The evidence is sufficient to determine that the technology results in an improvement in the net health outcome.

For individuals who have severe symptomatic aortic stenosis who are at intermediate risk for open surgery who receive TAVI, the evidence includes three RCTs comparing TAVI with surgical repair including individuals at intermediate surgical risk, two RCTs only in individuals with intermediate risk, and multiple systematic reviews and nonrandomized cohort studies. The relevant outcomes are OS, symptoms, morbid events, and treatment-related mortality and morbidity. Five RCTs have evaluated TAVI in individuals with intermediate risk for open surgery. Three of them, which included over 4,000 individuals combined, reported noninferiority of TAVI versus SAVR for their composite outcome measures (generally including death and stroke). A subset analysis of individuals (n=383) with low and intermediate surgical risk from a fourth trial reported higher rates of death at two years for TAVI vs SAVR. The final study (N=70) had an unclear hypothesis and reported 30-day mortality rates favoring SAVR (15% vs 2%, p=0.07) but used a transthoracic approach. The rates of adverse events differed between groups, with bleeding, cardiogenic shock, and acute kidney injury higher in individuals randomized to open surgery and permanent pacemaker requirement higher in individuals randomized to TAVI. Subgroup analyses of meta-analyses and the transthoracic arm of the Leon et al (2010) RCT have suggested that the benefit of TAVI may be limited to individuals who are candidates for transfemoral access. Although several RCTs have two years of follow-up postprocedure, it is uncertain how many individuals require reoperation. The evidence is sufficient to determine that the technology results in an improvement in the net health outcome.

For individuals who have severe symptomatic aortic stenosis who are at low risk for open surgery who receive TAVI, the evidence includes RCTs comparing TAVI with surgical repair in individuals selected without specific surgical risk criteria but including individuals at low surgical risk and RCTs enrolling only low surgical risk individuals, systematic reviews, and nonrandomized cohort studies. The relevant outcomes are OS, symptoms, morbid events, and treatment-related mortality and morbidity. Two RCTs (Evolut Low Risk Trial and the Study to Establish the Safety and Effectiveness of the SAPIEN 3 Transcatheter Heart Valve in Low-Risk



Individuals Who Have Severe, Calcific, Aortic Stenosis Requiring Aortic Valve Replacement [PARTNER 3]) have been conducted exclusively in individuals at low surgical risk and one RCT, Nordic Aortic Intervention Trial (NOTION), included predominantly individuals at low surgical risk. In the Evolut Low Risk Trial, transcatheter aortic valve replacement (TAVR) was noninferior to SAVR with respect to the composite outcome of death or disabling stroke at 24 months. In the PARTNER 3 trial, the rate of the composite of death, stroke, or rehospitalization at one year was significantly lower with TAVI than SAVR. In the NOTION trial, the risk of the composite outcome of death from any cause, stroke, or myocardial infarction (MI) at five years was similar for TAVI and SAVR and TAVR showed less structural valve deterioration than SAVR at six years. In the publicly sponsored UK TAVI trial, which was conducted in individuals aged 70 years or older with predominantly low surgical risk, TAVI was noninferior to SAVR with respect to all-cause mortality at one year. The evidence is sufficient to determine that the technology results in an improvement in the net health outcome.

For individuals who have valve dysfunction and aortic stenosis or regurgitation after open surgical aortic valve repair who receive transcatheter aortic “valve-in-valve” (ViV) implantation, the evidence includes observational studies including registry data with follow-up ranging from one month to five years and systematic reviews. The relevant outcomes are OS, symptoms, morbid events, and treatment-related mortality and morbidity. Recent meta-analyses of observational studies have compared ViV TAVI to redo-SAVR and have reported a reduced risk of short-term mortality (<30 days) with ViV TAVI. Beyond 30 days, meta-analyses have reported mortality outcomes that were similarly favorable or improved with redo-SAVR. The PARTNER 2 registry reported a 50.6% rate of all-cause mortality after five years among individuals with high surgical risk; individuals who received a 23-mm SAPIEN XT valve had a significantly higher risk of mortality compared to those who received a 26-mm valve (hazard ratio, 1.55; 95% confidence interval, 1.09 to 2.20;  $p=.01$ ). The CorHealth Ontario Cardiac Registry found that at 5 years after treatment, patients who underwent ViV TAVI had greater OS than rSAVR in a matched cohort of individuals (absolute risk difference, -7.5; 95% confidence interval, -12.6% to -2.3%). The Danish National Patient Registry found that ViV TAVI had similar mortality and rehospitalization outcomes compared to native valve TAVI at one- or five-years follow-up. Given that no RCTs are available, selection bias cannot be ruled out. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

For individuals who have symptomatic aortic stenosis who receive a cerebral embolic protection (CEP) device while undergoing TAVI, the evidence includes one meta-analysis and four RCTs of individuals with low- to high-risk for open surgery. Relevant outcomes are OS, symptoms, morbid events, and treatment-related mortality and morbidity. One meta-analysis found that patients with CEP had a lower rate of major adverse cardiac events, mortality, and stroke than patients with no CEP at 30 days post-TAVI; no differences were noted in the rate of vascular



complications, acute kidney injury, or major life-threatening bleeding. Three RCTs have primarily focused on the number and/or volume of new brain lesions detected on magnetic resonance imaging with unclear correlations to neurocognitive outcomes. Only one of these trials (CLEAN-TAVI) found a significant reduction in brain lesion number; however, the relevance of this trial is limited as it used a precursor to the currently marketed Sentinel device. The largest and most recent trial (PROTECTED TAVR) enrolled 3000 individuals and did not find a significant reduction in the incidence of periprocedural stroke within 72 hours or before hospital discharge. Prior trials have generally failed to demonstrate neurocognitive protection or significant reductions in major cardiac and cerebrovascular events. Studies have not stratified results by operative risk levels and have suggested differential benefits based on valve type. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

## Ongoing and Unpublished Clinical Trials

Some currently ongoing trials that might influence this policy are listed in [Table 1](#).

**Table 1. Summary of Key Trials**

NCT No.	Trial Name	Planned Enrollment	Completion Date
<b>Ongoing</b>			
<a href="#">NCT02701283</a>	Transcatheter Aortic Valve Replacement With the Medtronic Transcatheter Aortic Valve Replacement System In Patients at Low Risk for Surgical Aortic Valve Replacement	2223	Mar 2026
<a href="#">NCT05261204</a>	Transcatheter Aortic Valve Implantation Versus Standard Surgical Aortic Valve Operation for Aortic-Valve Stenosis in Patients at Risk to Severe Valve Obstruction.	1950	Mar 2024
<a href="#">NCT05002088<sup>a</sup></a>	Retrospective Assessment of the Portico Transcatheter Aortic Valve for Valve-in-Valve Use	100	Jun 2027
<a href="#">NCT03042104<sup>a</sup></a>	Evaluation of Transcatheter Aortic Valve Replacement Compared to Surveillance for Patients with Asymptomatic Severe Aortic Stenosis	901	Mar 2032
<a href="#">NCT03112980</a>	Randomized, Multi-Center, Event-Driven Trial of TAVI versus SAVR in Patients with Symptomatic Severe Aortic Valve Stenosis and Intermediate Risk of Mortality - DEDICATE	1417	Mar 2027



NCT No.	Trial Name	Planned Enrollment	Completion Date
<b>NCT01586910<sup>a</sup></b>	Surgical Replacement and Transcatheter Aortic Valve Implantation (SURTAVI)	1746 (actual enrollment)	Nov 2026
<b>NCT01057173</b>	Transcatheter Versus Surgical Aortic Valve Implantation in Patients With Severe Aortic Valve Stenosis (NOTION)	280	Apr 2033
<b>NCT01314313<sup>a</sup></b>	The PARTNER II Trial "Placement of AoRTic TraNscathetER Valves Trial" (US) [Edwards Study 2010-12]	2032	Nov 2024
<b>NCT02163850<sup>a</sup></b>	SALUS Trial: TranScatheter Aortic Valve Replacement System Pivotal Trial The Safety and Effectiveness of the Direct Flow Medical Transcatheter Aortic Valve System	878	Dec 2021 (unknown)
<b>NCT01737528</b>	Society of Thoracic Surgeons and American College of Cardiology Transcatheter Valve Therapy Registry (STS/ACC TVT Registry)	16,000	Jun 2035
<b>NCT02000115<sup>a</sup></b>	Portico Re-sheathable Transcatheter Aortic Valve System US IDE Trial	1150	Jul 2025
<b>NCT02825134<sup>a</sup></b>	Nordic Aortic Valve Intervention Trial 2 - A Randomized Multicenter Comparison of Transcatheter Versus Surgical Aortic Valve Replacement in Younger Low Surgical Risk Patients With Severe Aortic Stenosis (NOTION-2)	372	Jun 2029
<b>NCT02675114<sup>a</sup></b>	A Prospective, Randomized, Controlled, Multi-Center Study to Establish the Safety and Effectiveness of the SAPIEN 3 Transcatheter Heart Valve in Low Risk Patients Who Have Severe, Calcific, Aortic Stenosis Requiring Aortic Valve Replacement (PARTNER 3)	1000	Dec 2029

NCT: national clinical trial.

<sup>a</sup> Denotes industry-sponsored or cosponsored trial.

## Clinical Input Received from Physician Specialty Societies and Academic Medical Centers

While the various physician specialty societies and academic medical centers may collaborate with and make recommendations during this process, through the provision of appropriate reviewers, input received does not represent an endorsement or position statement by the physician specialty societies or academic medical centers, unless otherwise noted.



## 2024 Input

Clinical input was sought to help determine whether the use of transcatheter aortic valve-in-valve (ViV) implantation for individuals who have valve dysfunction and aortic stenosis or regurgitation after open surgical aortic valve repair provides a clinically meaningful improvement in net health outcome and whether the use is consistent with generally accepted medical practice. In response to requests, clinical input was received from 4 respondents, including: 3 physician-level responses with academic affiliations identified by specialty medical societies and 1 physician-level response identified by an academic health system.

For individuals with valve dysfunction and aortic stenosis or regurgitation after open surgical aortic valve repair, clinical input provides consistent support that the use of transcatheter ViV implantation provides a clinically meaningful improvement in the net health outcome and is consistent with generally accepted medical practice.

The following patient selection criteria for transcatheter aortic valve replacement (TAVR) with a transcatheter heart valve system approved for use for repair of a degenerated bioprosthetic valve (ViV) were informed by clinical input and the published evidence:

- Failure (stenosed, insufficient, or combined) of a surgical bioprosthetic aortic valve; AND
- New York Heart Association heart failure class II, III, or IV symptoms; AND
- Individual is not an operable candidate for open surgery, as documented by at least 2 cardiovascular specialists (including a cardiac surgeon); OR
- Individual is an operable candidate but is considered at increased surgical risk for open surgery, as documented by at least 2 cardiovascular specialists (including a cardiac surgeon; see Related Information section); OR
- Individual is considered at increased surgical risk for open surgery (e.g., repeat sternotomy) due to a history of congenital vascular anomalies AND/OR has a complex intrathoracic surgical history, as documented by at least 2 cardiovascular specialists (including a cardiac surgeon).

Respondents noted that there are certain technical impediments that may increase the risk of redo surgical aortic valve replacement (rSAVR) that are not captured by STS risk score, including porcelain aorta, prior mediastinal surgeries, patent bypass grafts, or a particularly adherent left internal mammary artery. Additionally, elderly individuals that do not meet high-risk criteria can benefit from the early recovery offered by TAVR. Clinical input also emphasized that there is



unlikely to be equipoise for randomization of patients with structural bioprosthetic valve degeneration to aortic valve replacement via any modality versus conservative therapy.

## 2016 Input

In response to requests, input was received from two specialty societies (one of which provided two responses) and two academic medical centers (one of which provided three responses) while this policy was under review in 2016. Although there was no support for the use of valve-in-valve TAVI to replace a failed bioprosthetic valve in general use, there was general support for the use of valve-in-valve TAVI for patients at high and prohibitive risk for surgery.

## 2014 Input

In response to requests, input was received from two specialty societies (one of which provided two responses) and six academic medical centers while this policy was under review in 2014. All reviewers who responded considered TAVI medically necessary for patients with severe aortic stenosis with a calcified aortic annulus and New York Heart Association functional class II, III, or IV symptoms, and who are not candidates for open surgery or who are operable candidates but are at high risk for open surgery. Most reviewers would require a patient to have a left ventricular ejection fraction greater than 20% for the procedure to be medically necessary. All reviewers indicated support for limiting the use of TAVI to patients who are not candidates for open surgery or who are operable candidates but are at high-risk for open surgery, and most supported using the FDA definition of high risk and extreme risk for surgery. Most reviewers noted that self-expanding valves have been associated with higher rates of postprocedural pacemaker requirements but that neither type of valve was clearly superior to the other.

## Practice Guidelines and Position Statements

The purpose of the following information is to provide reference material. Inclusion does not imply endorsement or alignment with the policy conclusions.

Guidelines or position statements will be considered for inclusion if they were issued by, or jointly by, a US professional society, an international society with US representation, or National Institute for Health and Care Excellence (NICE). Priority will be given to guidelines that are



informed by a systematic review, include strength of evidence ratings, and include a description of management of conflict of interest.

## American College of Cardiology and American Heart Association

In 2014, the American College of Cardiology and the American Heart Association published joint guidelines on the management of valvular heart disease.<sup>117</sup> Both groups issued a joint focused update in 2017.<sup>118</sup> In 2020, a new full guideline was published that replaces the 2014 revision and 2017 focused update.<sup>119</sup> The 2020 guidelines made the following recommendations on timing of intervention and choice of surgical or transcatheter intervention for treatment of aortic stenosis (see **Table 2**). Additionally, the guidelines state the following:

- "Treatment of severe aortic stenosis with either a transcatheter or surgical valve prosthesis should be based primarily on symptoms or reduced ventricular systolic function. Earlier intervention may be considered if indicated by results of exercise testing, biomarkers, rapid progression, or the presence of very severe stenosis."
- "Indications for TAVI are expanding as a result of multiple randomized trials of TAVI versus surgical aortic valve replacement. The choice of type of intervention for a patient with severe aortic stenosis should be a shared decision-making process that considers the lifetime risks and benefits associated with type of valve (mechanical versus bioprosthetic) and type of approach (transcatheter versus surgical)."

**Table 2. Recommendations on Surgical or Transcatheter Intervention for Aortic Stenosis**

Recommendation	COR	LOE
<i>Timing of Intervention of AS</i>		
"In adults with severe high-gradient AS (Stage D1) and symptoms of exertional dyspnea, heart failure, angina, syncope, or presyncope by history or on exercise testing, AVR is indicated."	I	A
"In asymptomatic patients with severe AS and a left ventricular ejection fraction <50% (Stage C2), AVR is indicated."	I	B
"In asymptomatic patients with severe AS (Stage C1) who are undergoing cardiac surgery for other indications, AVR is indicated."	I	B



"In symptomatic patients with low-flow, low-gradient severe AS with reduced left ventricular ejection fraction (Stage D2), AVR is recommended."	I	B
"In symptomatic patients with low-flow, low-gradient severe AS with reduced left ventricular ejection fraction (Stage D3), AVR is recommended if AS is the most likely cause of symptoms."	I	B
"In apparently asymptomatic patients with severe AS (Stage C1) and low surgical risk, AVR is reasonable when an exercise test demonstrates decreased exercise tolerance (normalized for age and sex) or a fall in systolic blood pressure of $\geq 10$ mmHg from baseline to peak exercise."	IIa	B
"In asymptomatic patients with very severe AS (defined as an aortic velocity of $\geq 5$ m/s) and low surgical risk, AVR is reasonable."	IIa	B
"In apparently asymptomatic patients with severe AS (Stage C1) and low surgical risk, AVR is reasonable when the serum B-type natriuretic peptide level is $>3$ times normal."	IIa	B
"In asymptomatic patients with high-gradient severe AS (Stage C1) and low surgical risk, AVR is reasonable when serial testing shows an increase in aortic velocity $\geq 0.3$ m/s per year."	IIa	B
"In asymptomatic patients with severe high-gradient AS (Stage C1) and a progressive decrease in left ventricular ejection fraction on at least 3 serial imaging studies to $<60\%$ , AVR may be considered."	IIb	B
"In patients with moderate AS (Stage B) who are undergoing cardiac surgery for other indications, AVR may be considered."	IIb	C
<b><i>Choice of SAVR Versus TAVI for Patients for Whom a Bioprosthetic AVR is Appropriate</i></b>		
"For symptomatic and asymptomatic patients with severe AS and any indication for AVR who are $<65$ years of age or have a life expectancy $>20$ years, SAVR is recommended."	I	A
"For symptomatic patients with severe AS who are 65 to 80 years of age and have no anatomic contraindication to transfemoral TAVI, either SAVR or transfemoral TAVI is recommended after shared decision-making about the balance between expected patient longevity and valve durability."	I	A
"For symptomatic patients with severe AS who are $>80$ years of age or for younger patients with a life expectancy of $< 10$ years and no anatomic contraindication to transfemoral TAVI, transfemoral TAVI is recommended in preference to SAVR."	I	A
"In asymptomatic patients with severe AS and a left ventricular ejection fraction $<50\%$ who are $\leq 80$ years of age and have no anatomic contraindication to transfemoral TAVI, the decision between TAVI and SAVR should follow the same recommendations as for symptomatic patients in the 3 recommendations above."	I	B
"For asymptomatic patients with severe AS and an abnormal exercise test, very severe AS, rapid progression, or an elevated B-type natriuretic peptide, SAVR is recommended in preference to TAVI."	I	B
"For patients with an indication for AVR for whom a bioprosthetic valve is preferred but valve or vascular anatomy or other factors are not suitable for transfemoral TAVI, SAVR is recommended."	I	A





"For symptomatic patients of any age with severe AS and a high or prohibitive surgical risk, TAVI is recommended if predicted post-TAVI survival is >12 months with an acceptable quality of life."	I	A
"For symptomatic patients with severe AS for whom predicted post-TAVI or post-SAVR survival is <12 months or for whom minimal improvement in quality of life is expected, palliative care is recommended after shared decision-making, including discussion of patient preferences and values."	I	C
"In critically ill patients with severe AS, percutaneous aortic balloon dilation may be considered as a bridge to SAVR or TAVI."	IIb	C
<b><i>Intervention for Prosthetic Valve Stenosis</i></b>		
"In patients with symptomatic severe stenosis of a bioprosthetic or mechanical prosthetic valve, repeat surgical intervention is indicated unless surgical risk is prohibitive."	I	B
"For severely symptomatic patients with bioprosthetic aortic valve stenosis and high or prohibitive surgical risk, a transcatheter ViV procedure is reasonable when performed at a Comprehensive Valve Center."	IIa	B
"For patients with significant bioprosthetic valve stenosis attributable to suspected or documented valve thrombosis, oral anticoagulation with a VKA is reasonable."	IIa	B
<b><i>Prosthetic Valve Regurgitation</i></b>		
"In patients with intractable hemolysis or HF attributable to prosthetic transvalvular or paravalvular leak, surgery is recommended unless surgical risk is high or prohibitive."	I	B
"In asymptomatic patients with severe prosthetic regurgitation and low operative risk, surgery is reasonable."	IIa	B
"In patients with prosthetic paravalvular regurgitation with the following: 1) either intractable hemolysis or NYHA class III or IV symptoms and 2) who are at high or prohibitive surgical risk and 3) have anatomic features suitable for catheter-based therapy, percutaneous repair of paravalvular leak is reasonable when performed at a Comprehensive Valve Center."	IIa	B
"For patients with severe HF symptoms caused by bioprosthetic valve regurgitation who are at high to prohibitive surgical risk, a transcatheter ViV procedure is reasonable when performed at a Comprehensive Valve Center."	IIa	B

AS: aortic stenosis; AVR: aortic valve replacement; COR: class of recommendation; HR: heart failure; LOE: level of evidence; SAVR: surgical aortic valve replacement; TAVI: transcatheter aortic valve implantation; ViV: valve-in-valve; VKA: vitamin K antagonist; NYHA: New York Heart Association.

## National Institute for Health and Care Excellence

In June 2019, the National Institute For Health And Care Excellence (NICE) published interventional procedures guidance [IPG653] regarding ViV TAVI for aortic bioprosthetic valve dysfunction.<sup>120</sup> The guidance was informed by an Interventional procedure overview described



previously.<sup>101</sup> The guidance recommendation is that "Current evidence on the safety and efficacy of valve-in-valve transcatheter aortic valve implantation (ViV-TAVI) for aortic bioprosthetic dysfunction is adequate to support the use of this procedure provided that standard arrangements are in place for clinical governance, consent and audit."

In November 2021, the NICE updated their guidance on heart valve disease. They recommend patients be offered TAVI if SAVR is contraindicated or the patient is at high surgical risk.<sup>121</sup>

## Medicare National Coverage

The Centers for Medicare & Medicaid Services published a decision memo on the use of TAVR in 2012 and 2019.<sup>122</sup> The 2019 memo indicated that Centers for Medicare & Medicaid Services covers TAVI when used according to FDA indications when the following conditions are met:

- Device has FDA approval.
- The patient (preoperatively and postoperatively) is under the care of a heart team including an experienced cardiac surgeon and interventional cardiologist, who have independently examined the patient, as well as providers from other physician groups, advanced patient practitioners, nurses, research personnel and administrators
- The interventional cardiologist(s) and cardiac surgeon(s) jointly participate in the intra-operative technical aspects of TAVR
- The hospital meets qualifications for performing TAVR
- The heart team and hospital are participating in a prospective, national, audited registry that follows patients for at least one year and collects specific patient, practitioner and facility level outcomes
- The registry collects necessary data and has an analysis plan to address specific questions and results are reported publicly

The memo also stated that TAVR could be covered for non-FDA-approved indications under the Coverage with Evidence Development program. The following is a summary of the main conditions required for Coverage with Evidence Development:

- The interventional cardiologist(s) and cardiac surgeon(s) jointly participate in the intra-operative technical aspects of TAVR

TAVR is performed within a clinical study that has the following characteristics:



- “The clinical study must adhere to the... standards of scientific integrity and relevance to the Medicare population.”
- The study must address quality of life and adverse events at follow-up periods of one year or longer.

The decision memo does not address concurrent use of a cerebral embolic protection device.

## Regulatory Status

Multiple manufacturers have transcatheter aortic valve devices with US Food and Drug Administration (FDA) approval. Regulatory status data for these devices are listed in [Table 3](#).

**Table 3. FDA-Approved Transcatheter Aortic Valve Device Systems**

Device and Indication	Manufacturer	Date Cleared	PMA
Edwards SAPIEN Transcatheter Heart Valve System Severe native aortic valve stenosis determined to be inoperable for open aortic valve replacement (transfemoral approach)	Edwards Lifesciences	11/11	P100041
Edwards SAPIEN Transcatheter Heart Valve, Model 9000TFX Expanded to include high-risk aortic stenosis (transapical approach)	Edwards Lifesciences	10/12	P110021
Edwards SAPIEN XT Transcatheter Heart Valve (model 9300TFX) and accessories Severe native aortic valve stenosis at high or greater risk for open surgical therapy	Edwards Lifesciences	07/14	P130009
Expanded to include failure of bioprosthetic valve in high or greater risk for open surgical therapy	Edwards Lifesciences	10/15	P130009/ S034
Expanded to include severe aortic stenosis with intermediate surgical risk	Edwards Lifesciences	08/16	P130009/ S057
SAPIEN 3 THV System, a design iteration Severe aortic stenosis with high or greater risk for open surgical therapy	Edwards Lifesciences	6/15	P140031
Expanded to include failure of a bioprosthetic valve with high or greater risk for open surgical therapy	Edwards Lifesciences	6/17	P140031/ S028



Device and Indication	Manufacturer	Date Cleared	PMA
SAPIEN 3 Ultra THV System, a design iteration  Note: In August 2019, FDA issued a recall for the Edwards SAPIEN 3 Ultra Transcatheter Heart Valve System (Recall event ID: 83293) due to “reports of burst balloons which have resulted in significant difficulty retrieving the device into the sheath and withdrawing the system from the patient during procedures”	Edwards Lifesciences	12/18	P140031
Expanded to include severe aortic stenosis with low surgical risk	Edwards Lifesciences	08/19	P140031/S085
Expanded to include failure of a bioprosthetic valve with high or greater risk for open surgical therapy	Edwards Lifesciences	09/20	P140031/S112
Medtronic CoreValve System  Severe native aortic stenosis at extreme risk or inoperable for open surgical therapy	Medtronic CoreValve	01/14	P130021
Expanded to include high risk for open surgical therapy	Medtronic CoreValve	06/16	P130021/S002
Expanded to include intermediate risk for open surgical therapy	Medtronic CoreValve	07/17	P130021/S033
Medtronic CoreValve Evolut R System  Design iteration for valve and accessories	Medtronic CoreValve	06/15	P130021/S014
Expanded to include intermediate risk for open surgical therapy	Medtronic CoreValve	07/17	P130021/S033
Medtronic CoreValve Evolut PRO System  Design iteration for valve and accessories, includes porcine pericardial tissue wrap	Medtronic CoreValve	03/17	P130021/S029
Expanded to include intermediate risk for open surgical therapy	Medtronic CoreValve	07/17	P130021/S033
Expanded to include severe aortic stenosis with low surgical risk	Medtronic CoreValve	08/19	P130021/S058
Medtronic CoreValve Evolut PRO+ System (design iteration)	Medtronic CoreValve	08/19	P130021/S059
Medtronic EvolutFX System (design iteration)	Medtronic CoreValve	8/21	P130021/S091
LOTUS Edge Valve System  Severe native aortic stenosis at high or greater risk for open surgical therapy	Boston Scientific Corporation	04/19	P180029



Device and Indication	Manufacturer	Date Cleared	PMA
(See Note below)			
Portico with FlexNav Severe native aortic stenosis at high or greater risk for open surgical therapy	Abbott Medical	09/21	P190023
Navitor Transcatheter Aortic Valve Implantation System with FlexNav Severe native aortic stenosis at high or greater risk for open surgical therapy	Abbott Medical	10/23	P190023/ S016

FDA: US Food and Drug Administration: PMA: premarket approval.

**Note:** In January 2021, Boston Scientific Corporation announced a global, voluntary recall of all unused inventory of the LOTUS Edge Valve System due to complexities associated with the product delivery system.<sup>9</sup> There are no safety concerns for patients who have the LOTUS Edge Valve System currently implanted. Boston Scientific has chosen to retire the entire LOTUS product platform immediately rather than develop and reintroduce an enhanced delivery system. All related commercial, clinical, research and development, and manufacturing activities will cease.

Other transcatheter aortic valve systems are under development:

- JenaValve (JenaValve Technology); repositionable valve designed for transapical placement. The FDA granted breakthrough designation to this device system in January 2020.
- Acurate aortic valve platform (Boston Scientific); designed for individuals with severe aortic stenosis indicated for transcatheter aortic valve replacement who are at low, intermediate, or high risk of operative mortality. The system received Conformité Européene (CE) mark approval in Europe as of 2020 but is not approved for non-investigational use in the US. The pivotal Acurate IDE trial will be completed in 2024 (NCT03735667)

In June 2017, the Sentinel Cerebral Protection System (Boston Scientific, previously Claret Medical, Inc.) was granted a de novo classification by the FDA (DEN160043; class II; product code: PUM.)<sup>10</sup> The Sentinel system is a temporary catheter indicated for use as an embolic protection device to capture and remove thrombus/debris while performing transcatheter aortic valve replacement procedures. The diameters of the arteries at the site of filter placement should be between 9 mm to 15 mm for the brachiocephalic and 6.5 mm to 10 mm in the left common carotid. The new classification applies to this device and substantially equivalent devices of this generic type.



On August 3, 2021, the FDA Circulatory System Devices Panel of the Medical Devices Advisory Committee met to discuss and make recommendations on the 510(k) submission for the TriGUARD 3 Cerebral Embolic Protection Device (Keystone Heart).<sup>11</sup> With the Sentinel system serving as the predicate device, the panel expressed that the proposed indications for use of the TriGUARD 3 device were not supported by the safety and effectiveness data from the REFLECT II trial. Previously, the TriGUARD 3 device was granted Conformité Européene (CE) mark approval in Europe in March 2020.<sup>12,11</sup>

## References

1. Carroll JD, Mack MJ, Vemulapalli S, et al. STS-ACC TVT Registry of Transcatheter Aortic Valve Replacement. *Ann Thorac Surg*. Feb 2021; 111(2): 701-722. PMID 33213826
2. Kumar A, Sato K, Narayanswami J, et al. Current Society of Thoracic Surgeons Model Reclassifies Mortality Risk in Patients Undergoing Transcatheter Aortic Valve Replacement. *Circ Cardiovasc Interv*. Sep 2018; 11(9): e006664. PMID 30354591
3. Freeman RV, Otto CM. Spectrum of calcific aortic valve disease: pathogenesis, disease progression, and treatment strategies. *Circulation*. Jun 21 2005; 111(24): 3316-26. PMID 15967862
4. Coeytaux RR, Williams JW, Gray RN, et al. Percutaneous heart valve replacement for aortic stenosis: state of the evidence. *Ann Intern Med*. Sep 07 2010; 153(5): 314-24. PMID 20679543
5. Lindroos M, Kupari M, Heikkilä J, et al. Prevalence of aortic valve abnormalities in the elderly: an echocardiographic study of a random population sample. *J Am Coll Cardiol*. Apr 1993; 21(5): 1220-5. PMID 8459080
6. Bonow RO, Carabello BA, Kanu C, et al. ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (writing committee to revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease): developed in collaboration with the Society of Cardiovascular Anesthesiologists: endorsed by the Society for Cardiovascular Angiography and Interventions and the Society of Thoracic Surgeons. *Circulation*. Aug 01 2006; 114(5): e84-231. PMID 16880336
7. Lung B, Cachier A, Baron G, et al. Decision-making in elderly patients with severe aortic stenosis: why are so many denied surgery?. *Eur Heart J*. Dec 2005; 26(24): 2714-20. PMID 16141261
8. Lieberman EB, Bashore TM, Hermiller JB, et al. Balloon aortic valvuloplasty in adults: failure of procedure to improve long-term survival. *J Am Coll Cardiol*. Nov 15 1995; 26(6): 1522-8. PMID 7594080
9. Food and Drug Administration (FDA). Boston Scientific announces LOTUS Edge aortic valve system voluntary recall and product discontinuation. January 11, 2021. <https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/boston-scientific-announces-lotus-edgetm-aortic-valve-system-voluntary-recall-and-product>. Accessed March 8, 2024.
10. Food and Drug Administration (FDA). De Novo Classification Request for Sentinel Cerebral Protection System. September 19, 2016; [https://www.accessdata.fda.gov/cdrh\\_docs/reviews/DEN160043.pdf](https://www.accessdata.fda.gov/cdrh_docs/reviews/DEN160043.pdf). Accessed on March 8, 2024.
11. Food and Drug Administration (FDA). 24 Hour Summary of the Circulatory System Devices Panel Meeting - Keystone Heart, Ltd TriGUARD 3 Cerebral Embolic Protection Device. August 3, 2021; <https://www.fda.gov/media/151335/download>. Accessed March 8, 2024.
12. Aladin AI, Case BC, Wermers JP, et al. Overview of FDA Circulatory System Devices Panel virtual meeting on TriGUARD 3 cerebral embolic protection. *Catheter Cardiovasc Interv*. May 2022; 99(6): 1789-1795. PMID 35084082



13. Spertus J, Peterson E, Conard MW, et al. Monitoring clinical changes in patients with heart failure: a comparison of methods. *Am Heart J.* Oct 2005; 150(4): 707-15. PMID 16209970
14. Figulla L, Neumann A, Figulla HR, et al. Transcatheter aortic valve implantation: evidence on safety and efficacy compared with medical therapy. A systematic review of current literature. *Clin Res Cardiol.* Apr 2011; 100(4): 265-76. PMID 21165626
15. Leon MB, Smith CR, Mack M, et al. Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery. *N Engl J Med.* Oct 21 2010; 363(17): 1597-607. PMID 20961243
16. Reynolds MR, Magnuson EA, Lei Y, et al. Health-related quality of life after transcatheter aortic valve replacement in inoperable patients with severe aortic stenosis. *Circulation.* Nov 01 2011; 124(18): 1964-72. PMID 21969017
17. Makkar RR, Fontana GP, Jilaihawi H, et al. Transcatheter aortic-valve replacement for inoperable severe aortic stenosis. *N Engl J Med.* May 03 2012; 366(18): 1696-704. PMID 22443478
18. Svensson LG, Blackstone EH, Rajeswaran J, et al. Comprehensive analysis of mortality among patients undergoing TAVR: results of the PARTNER trial. *J Am Coll Cardiol.* Jul 15 2014; 64(2): 158-68. PMID 25011720
19. Kapadia SR, Tuzcu EM, Makkar RR, et al. Long-term outcomes of inoperable patients with aortic stenosis randomly assigned to transcatheter aortic valve replacement or standard therapy. *Circulation.* Oct 21 2014; 130(17): 1483-92. PMID 25205802
20. Webb JG, Doshi D, Mack MJ, et al. A Randomized Evaluation of the SAPIEN XT Transcatheter Heart Valve System in Patients With Aortic Stenosis Who Are Not Candidates for Surgery. *JACC Cardiovasc Interv.* Dec 21 2015; 8(14): 1797-806. PMID 26718510
21. Kapadia SR, Huded CP, Kodali SK, et al. Stroke After Surgical Versus Transfemoral Transcatheter Aortic Valve Replacement in the PARTNER Trial. *J Am Coll Cardiol.* Nov 13 2018; 72(20): 2415-2426. PMID 30442284
22. Huded CP, Arnold SV, Chhatriwalla AK, et al. Rehospitalization Events After Aortic Valve Replacement: Insights From the PARTNER Trial. *Circ Cardiovasc Interv.* Dec 2022; 15(12): e012195. PMID 36538580
23. Popma JJ, Adams DH, Reardon MJ, et al. Transcatheter aortic valve replacement using a self-expanding bioprosthesis in patients with severe aortic stenosis at extreme risk for surgery. *J Am Coll Cardiol.* May 20 2014; 63(19): 1972-81. PMID 24657695
24. Reardon MJ, Adams DH, Coselli JS, et al. Self-expanding transcatheter aortic valve replacement using alternative access sites in symptomatic patients with severe aortic stenosis deemed extreme risk of surgery. *J Thorac Cardiovasc Surg.* Dec 2014; 148(6): 2869-76.e1-7. PMID 25152474
25. Mack MJ, Brennan JM, Brindis R, et al. Outcomes following transcatheter aortic valve replacement in the United States. *JAMA.* Nov 20 2013; 310(19): 2069-77. PMID 24240934
26. Yakubov SJ, Adams DH, Watson DR, et al. 2-Year Outcomes After Iliofemoral Self-Expanding Transcatheter Aortic Valve Replacement in Patients With Severe Aortic Stenosis Deemed Extreme Risk for Surgery. *J Am Coll Cardiol.* Sep 22 2015; 66(12): 1327-34. PMID 26383718
27. Baron SJ, Arnold SV, Reynolds MR, et al. Durability of quality of life benefits of transcatheter aortic valve replacement: Long-term results from the CoreValve US extreme risk trial. *Am Heart J.* Dec 2017; 194: 39-48. PMID 29223434
28. Arnold SV, Petrossian G, Reardon MJ, et al. Five-Year Clinical and Quality of Life Outcomes From the CoreValve US Pivotal Extreme Risk Trial. *Circ Cardiovasc Interv.* Jun 2021; 14(6): e010258. PMID 34092091
29. Osnabrugge RL, Arnold SV, Reynolds MR, et al. Health status after transcatheter aortic valve replacement in patients at extreme surgical risk: results from the CoreValve U.S. trial. *JACC Cardiovasc Interv.* Feb 2015; 8(2): 315-323. PMID 25700755
30. Linke A, Wenaweser P, Gerckens U, et al. Treatment of aortic stenosis with a self-expanding transcatheter valve: the International Multi-centre ADVANCE Study. *Eur Heart J.* Oct 07 2014; 35(38): 2672-84. PMID 24682842
31. Piazza N, Grube E, Gerckens U, et al. Procedural and 30-day outcomes following transcatheter aortic valve implantation using the third generation (18 Fr) corevalve revalving system: results from the multicentre, expanded evaluation registry 1-year following CE mark approval. *EuroIntervention.* Aug 2008; 4(2): 242-9. PMID 19110790



32. Rodés-Cabau J, Webb JG, Cheung A, et al. Transcatheter aortic valve implantation for the treatment of severe symptomatic aortic stenosis in patients at very high or prohibitive surgical risk: acute and late outcomes of the multicenter Canadian experience. *J Am Coll Cardiol*. Mar 16 2010; 55(11): 1080-90. PMID 20096533
33. Zahn R, Gerckens U, Grube E, et al. Transcatheter aortic valve implantation: first results from a multi-centre real-world registry. *Eur Heart J*. Jan 2011; 32(2): 198-204. PMID 20864486
34. Tamburino C, Capodanno D, Ramondo A, et al. Incidence and predictors of early and late mortality after transcatheter aortic valve implantation in 663 patients with severe aortic stenosis. *Circulation*. Jan 25 2011; 123(3): 299-308. PMID 21220731
35. Panoulas VF, Francis DP, Ruparelia N, et al. Female-specific survival advantage from transcatheter aortic valve implantation over surgical aortic valve replacement: Meta-analysis of the gender subgroups of randomised controlled trials including 3758 patients. *Int J Cardiol*. Jan 01 2018; 250: 66-72. PMID 29169764
36. Dagan M, Yeung T, Stehli J, et al. Transcatheter Versus Surgical Aortic Valve Replacement: An Updated Systematic Review and Meta-Analysis With a Focus on Outcomes by Sex. *Heart Lung Circ*. Jan 2021; 30(1): 86-99. PMID 32732125
37. Villablanca PA, Mathew V, Thourani VH, et al. A meta-analysis and meta-regression of long-term outcomes of transcatheter versus surgical aortic valve replacement for severe aortic stenosis. *Int J Cardiol*. Dec 15 2016; 225: 234-243. PMID 27732927
38. Mack MJ, Leon MB, Smith CR, et al. 5-year outcomes of transcatheter aortic valve replacement or surgical aortic valve replacement for high surgical risk patients with aortic stenosis (PARTNER 1): a randomised controlled trial. *Lancet*. Jun 20 2015; 385(9986): 2477-84. PMID 25788234
39. Reardon MJ, Adams DH, Kleiman NS, et al. 2-Year Outcomes in Patients Undergoing Surgical or Self-Expanding Transcatheter Aortic Valve Replacement. *J Am Coll Cardiol*. Jul 14 2015; 66(2): 113-21. PMID 26055947
40. Panchal HB, Ladia V, Desai S, et al. A meta-analysis of mortality and major adverse cardiovascular and cerebrovascular events following transcatheter aortic valve implantation versus surgical aortic valve replacement for severe aortic stenosis. *Am J Cardiol*. Sep 15 2013; 112(6): 850-60. PMID 23756547
41. Takagi H, Niwa M, Mizuno Y, et al. A meta-analysis of transcatheter aortic valve implantation versus surgical aortic valve replacement. *Ann Thorac Surg*. Aug 2013; 96(2): 513-9. PMID 23816417
42. Smith CR, Leon MB, Mack MJ, et al. Transcatheter versus surgical aortic-valve replacement in high-risk patients. *N Engl J Med*. Jun 09 2011; 364(23): 2187-98. PMID 21639811
43. Reynolds MR, Magnuson EA, Wang K, et al. Health-related quality of life after transcatheter or surgical aortic valve replacement in high-risk patients with severe aortic stenosis: results from the PARTNER (Placement of AoRTic TraNscathetER Valve) Trial (Cohort A). *J Am Coll Cardiol*. Aug 07 2012; 60(6): 548-58. PMID 22818074
44. Généreux P, Cohen DJ, Williams MR, et al. Bleeding complications after surgical aortic valve replacement compared with transcatheter aortic valve replacement: insights from the PARTNER I Trial (Placement of Aortic Transcatheter Valve). *J Am Coll Cardiol*. Mar 25 2014; 63(11): 1100-9. PMID 24291283
45. Adams DH, Popma JJ, Reardon MJ, et al. Transcatheter aortic-valve replacement with a self-expanding prosthesis. *N Engl J Med*. May 08 2014; 370(19): 1790-8. PMID 24678937
46. Deeb GM, Reardon MJ, Chetcuti S, et al. 3-Year Outcomes in High-Risk Patients Who Underwent Surgical or Transcatheter Aortic Valve Replacement. *J Am Coll Cardiol*. Jun 07 2016; 67(22): 2565-74. PMID 27050187
47. Zorn GL, Little SH, Tadros P, et al. Prosthesis-patient mismatch in high-risk patients with severe aortic stenosis: A randomized trial of a self-expanding prosthesis. *J Thorac Cardiovasc Surg*. Apr 2016; 151(4): 1014-22, 1023.e1-3. PMID 26614412
48. Arnold SV, Chinnakondepalli KM, Magnuson EA, et al. Five-Year Health Status After Self-expanding Transcatheter or Surgical Aortic Valve Replacement in High-risk Patients With Severe Aortic Stenosis. *JAMA Cardiol*. Jan 01 2021; 6(1): 97-101. PMID 32997095
49. Conte JV, Hermiller J, Resar JR, et al. Complications After Self-expanding Transcatheter or Surgical Aortic Valve Replacement. *Semin Thorac Cardiovasc Surg*. Autumn 2017; 29(3): 321-330. PMID 29195573





50. Gleason TG, Reardon MJ, Popma JJ, et al. 5-Year Outcomes of Self-Expanding Transcatheter Versus Surgical Aortic Valve Replacement in High-Risk Patients. *J Am Coll Cardiol.* Dec 04 2018; 72(22): 2687-2696. PMID 30249462
51. Makkar RR, Cheng W, Waksman R, et al. Self-expanding intra-annular versus commercially available transcatheter heart valves in high and extreme risk patients with severe aortic stenosis (PORTICO IDE): a randomised, controlled, non-inferiority trial. *Lancet.* Sep 05 2020; 396(10252): 669-683. PMID 32593323
52. Muneretto C, Bisleri G, Moggi A, et al. Treating the patients in the 'grey-zone' with aortic valve disease: a comparison among conventional surgery, sutureless valves and transcatheter aortic valve replacement. *Interact Cardiovasc Thorac Surg.* Jan 2015; 20(1): 90-5. PMID 25320140
53. Minutello RM, Wong SC, Swaminathan RV, et al. Costs and in-hospital outcomes of transcatheter aortic valve implantation versus surgical aortic valve replacement in commercial cases using a propensity score matched model. *Am J Cardiol.* May 15 2015; 115(10): 1443-7. PMID 25784513
54. Sedaghat A, Al-Rashid F, Sinning JM, et al. Outcome in TAVI patients with symptomatic aortic stenosis not fulfilling PARTNER study inclusion criteria. *Catheter Cardiovasc Interv.* Nov 15 2015; 86(6): 1097-104. PMID 26032437
55. Arora S, Strassle PD, Ramm CJ, et al. Transcatheter Versus Surgical Aortic Valve Replacement in Patients With Lower Surgical Risk Scores: A Systematic Review and Meta-Analysis of Early Outcomes. *Heart Lung Circ.* Aug 2017; 26(8): 840-845. PMID 28169084
56. Arora S, Vaidya SR, Strassle PD, et al. Meta-analysis of transfemoral TAVR versus surgical aortic valve replacement. *Catheter Cardiovasc Interv.* Mar 01 2018; 91(4): 806-812. PMID 29068166
57. Garg A, Rao SV, Visveswaran G, et al. Transcatheter Aortic Valve Replacement Versus Surgical Valve Replacement in Low-Intermediate Surgical Risk Patients: A Systematic Review and Meta-Analysis. *J Invasive Cardiol.* Jun 2017; 29(6): 209-216. PMID 28570236
58. Singh K, Carson K, Rashid MK, et al. Transcatheter Aortic Valve Implantation in Intermediate Surgical Risk Patients With Severe Aortic Stenosis: A Systematic Review and Meta-Analysis. *Heart Lung Circ.* Feb 2018; 27(2): 227-234. PMID 28473216
59. Ando T, Takagi H, Grines CL. Transfemoral, transapical and transcatheter aortic valve implantation and surgical aortic valve replacement: a meta-analysis of direct and adjusted indirect comparisons of early and mid-term deaths. *Interact Cardiovasc Thorac Surg.* Sep 01 2017; 25(3): 484-492. PMID 28549125
60. Gozdek M, Raffa GM, Suwalski P, et al. Comparative performance of transcatheter aortic valve-in-valve implantation versus conventional surgical redo aortic valve replacement in patients with degenerated aortic valve bioprostheses: systematic review and meta-analysis. *Eur J Cardiothorac Surg.* Mar 01 2018; 53(3): 495-504. PMID 29029105
61. Khan SU, Lone AN, Saleem MA, et al. Transcatheter vs surgical aortic-valve replacement in low- to intermediate-surgical-risk candidates: A meta-analysis and systematic review. *Clin Cardiol.* Nov 2017; 40(11): 974-981. PMID 29168984
62. Tam DY, Vo TX, Wijeyesundera HC, et al. Transcatheter vs Surgical Aortic Valve Replacement for Aortic Stenosis in Low-Intermediate Risk Patients: A Meta-analysis. *Can J Cardiol.* Sep 2017; 33(9): 1171-1179. PMID 28843328
63. Witberg G, Lador A, Yahav D, et al. Transcatheter versus surgical aortic valve replacement in patients at low surgical risk: A meta-analysis of randomized trials and propensity score matched observational studies. *Catheter Cardiovasc Interv.* Aug 01 2018; 92(2): 408-416. PMID 29388308
64. Ueshima D, Fovino LN, D'Amico G, et al. Transcatheter versus surgical aortic valve replacement in low- and intermediate-risk patients: an updated systematic review and meta-analysis. *Cardiovasc Interv Ther.* Jul 2019; 34(3): 216-225. PMID 30232711
65. Levett JY, Windle SB, Filion KB, et al. Meta-Analysis of Transcatheter Versus Surgical Aortic Valve Replacement in Low Surgical Risk Patients. *Am J Cardiol.* Apr 15 2020; 125(8): 1230-1238. PMID 32089249
66. Vipparthy SC, Ravi V, Avula S, et al. Meta-Analysis of Transcatheter Aortic Valve Implantation Versus Surgical Aortic Valve Replacement in Patients With Low Surgical Risk. *Am J Cardiol.* Feb 01 2020; 125(3): 459-468. PMID 31784051
67. Anantha-Narayanan M, Kandasamy VV, Reddy YN, et al. Low-Risk Transcatheter Versus Surgical Aortic Valve Replacement - An Updated Meta-Analysis of Randomized Controlled Trials. *Cardiovasc Revasc Med.* Apr 2020; 21(4): 441-452. PMID 31678116



68. Kundu A, Sardar P, Malhotra R, et al. Cardiovascular Outcomes with Transcatheter vs. Surgical Aortic Valve Replacement in Low-Risk Patients: An Updated Meta-Analysis of Randomized Controlled Trials. *Cardiovasc Revasc Med*. Apr 2020; 21(4): 453-460. PMID 31669113
69. Sá MP, Jacquemyn X, Van den Eynde J, et al. Midterm Survival of Low-Risk Patients Treated With Transcatheter Versus Surgical Aortic Valve Replacement: Meta-Analysis of Reconstructed Time-to-Event Data. *J Am Heart Assoc*. Nov 07 2023; 12(21): e030012. PMID 37929669
70. Lerman TT, Levi A, Kornowski R. Meta-analysis of short- and long-term clinical outcomes of the self-expanding Evolut R/pro valve versus the balloon-expandable Sapien 3 valve for transcatheter aortic valve implantation. *Int J Cardiol*. Jan 15 2023; 371: 100-108. PMID 36130623
71. Improta R, Di Pietro G, Kola N, et al. A Meta-Analysis of Short-Term Outcomes of TAVR versus SAVR in Bicuspid Aortic Valve Stenosis and TAVR Results in Different Bicuspid Valve Anatomies. *J Clin Med*. Nov 28 2023; 12(23). PMID 38068423
72. Acconcia MC, Perrone MA, Sergi D, et al. Transcatheter aortic valve implantation results are not superimposable to surgery in patients with aortic stenosis at low surgical risk. *Cardiol J*. 2023; 30(4): 595-605. PMID 34622437
73. Park DY, An S, Kassab K, et al. Chronological comparison of TAVI and SAVR stratified to surgical risk: a systematic review, meta-analysis, and meta-regression. *Acta Cardiol*. Sep 2023; 78(7): 778-789. PMID 37294002
74. Kolkailah AA, Doukky R, Pelletier MP, et al. Cochrane corner: transcatheter aortic valve implantation versus surgical aortic valve replacement for severe aortic stenosis in people with low surgical risk. *Heart*. Jul 2020; 106(14): 1043-1045. PMID 32482670
75. Zhou Y, Wang Y, Wu Y, et al. Transcatheter versus surgical aortic valve replacement in low to intermediate risk patients: A meta-analysis of randomized and observational studies. *Int J Cardiol*. Feb 01 2017; 228: 723-728. PMID 27886617
76. Thyregod HG, Steinbrüchel DA, Ihlemann N, et al. Transcatheter Versus Surgical Aortic Valve Replacement in Patients With Severe Aortic Valve Stenosis: 1-Year Results From the All-Comers NOTION Randomized Clinical Trial. *J Am Coll Cardiol*. May 26 2015; 65(20): 2184-94. PMID 25787196
77. Nielsen HH, Klaaborg KE, Nissen H, et al. A prospective, randomised trial of transapical transcatheter aortic valve implantation vs. surgical aortic valve replacement in operable elderly patients with aortic stenosis: the STACCATO trial. *EuroIntervention*. Jul 20 2012; 8(3): 383-9. PMID 22581299
78. Leon MB, Smith CR, Mack MJ, et al. Transcatheter or Surgical Aortic-Valve Replacement in Intermediate-Risk Patients. *N Engl J Med*. Apr 28 2016; 374(17): 1609-20. PMID 27040324
79. Kondur A, Briasoulis A, Palla M, et al. Meta-Analysis of Transcatheter Aortic Valve Replacement Versus Surgical Aortic Valve Replacement in Patients With Severe Aortic Valve Stenosis. *Am J Cardiol*. Jan 15 2016; 117(2): 252-7. PMID 26639040
80. Tamburino C, Barbanti M, D'Errigo P, et al. 1-Year Outcomes After Transfemoral Transcatheter or Surgical Aortic Valve Replacement: Results From the Italian OBSERVANT Study. *J Am Coll Cardiol*. Aug 18 2015; 66(7): 804-812. PMID 26271063
81. Siemieniuk RA, Agoritsas T, Manja V, et al. Transcatheter versus surgical aortic valve replacement in patients with severe aortic stenosis at low and intermediate risk: systematic review and meta-analysis. *BMJ*. Sep 28 2016; 354: i5130. PMID 27683246
82. Søndergaard L, Steinbrüchel DA, Ihlemann N, et al. Two-Year Outcomes in Patients With Severe Aortic Valve Stenosis Randomized to Transcatheter Versus Surgical Aortic Valve Replacement: The All-Comers Nordic Aortic Valve Intervention Randomized Clinical Trial. *Circ Cardiovasc Interv*. Jun 2016; 9(6). PMID 27296202
83. Thyregod HGH, Ihlemann N, Jørgensen TH, et al. Five-Year Clinical and Echocardiographic Outcomes From the NOTION Randomized Clinical Trial in Patients at Lower Surgical Risk. *Circulation*. Jun 11 2019; 139(24): 2714-2723. PMID 30704298
84. Søndergaard L, Ihlemann N, Capodanno D, et al. Durability of Transcatheter and Surgical Bioprosthetic Aortic Valves in Patients at Lower Surgical Risk. *J Am Coll Cardiol*. Feb 12 2019; 73(5): 546-553. PMID 30732707
85. Reardon MJ, Kleiman NS, Adams DH, et al. Outcomes in the Randomized CoreValve US Pivotal High Risk Trial in Patients With a Society of Thoracic Surgeons Risk Score of 7% or Less. *JAMA Cardiol*. Nov 01 2016; 1(8): 945-949. PMID 27541162



86. Reardon MJ, Van Mieghem NM, Popma JJ, et al. Surgical or Transcatheter Aortic-Valve Replacement in Intermediate-Risk Patients. *N Engl J Med.* Apr 06 2017; 376(14): 1321-1331. PMID 28304219
87. Van Mieghem NM, Deeb GM, Søndergaard L, et al. Self-expanding Transcatheter vs Surgical Aortic Valve Replacement in Intermediate-Risk Patients: 5-Year Outcomes of the SURTAVI Randomized Clinical Trial. *JAMA Cardiol.* Oct 01 2022; 7(10): 1000-1008. PMID 36001335
88. Popma JJ, Deeb GM, Yakubov SJ, et al. Transcatheter Aortic-Valve Replacement with a Self-Expanding Valve in Low-Risk Patients. *N Engl J Med.* May 02 2019; 380(18): 1706-1715. PMID 30883053
89. Forrest JK, Deeb GM, Yakubov SJ, et al. 2-Year Outcomes After Transcatheter Versus Surgical Aortic Valve Replacement in Low-Risk Patients. *J Am Coll Cardiol.* Mar 08 2022; 79(9): 882-896. PMID 35241222
90. Forrest JK, Deeb GM, Yakubov SJ, et al. 3-Year Outcomes After Transcatheter or Surgical Aortic Valve Replacement in Low-Risk Patients With Aortic Stenosis. *J Am Coll Cardiol.* May 02 2023; 81(17): 1663-1674. PMID 36882136
91. Mack MJ, Leon MB, Thourani VH, et al. Transcatheter Aortic-Valve Replacement with a Balloon-Expandable Valve in Low-Risk Patients. *N Engl J Med.* May 02 2019; 380(18): 1695-1705. PMID 30883058
92. Leon MB, Mack MJ, Hahn RT, et al. Outcomes 2 Years After Transcatheter Aortic Valve Replacement in Patients at Low Surgical Risk. *J Am Coll Cardiol.* Mar 09 2021; 77(9): 1149-1161. PMID 33663731
93. Toff WD, Hildick-Smith D, Kovac J, et al. Effect of Transcatheter Aortic Valve Implantation vs Surgical Aortic Valve Replacement on All-Cause Mortality in Patients With Aortic Stenosis: A Randomized Clinical Trial. *JAMA.* May 17 2022; 327(19): 1875-1887. PMID 35579641
94. Jørgensen TH, Thyregod HGH, Ihlemann N, et al. Eight-year outcomes for patients with aortic valve stenosis at low surgical risk randomized to transcatheter vs. surgical aortic valve replacement. *Eur Heart J.* Aug 07 2021; 42(30): 2912-2919. PMID 34179981
95. Makkar RR, Thourani VH, Mack MJ, et al. Five-Year Outcomes of Transcatheter or Surgical Aortic-Valve Replacement. *N Engl J Med.* Feb 27 2020; 382(9): 799-809. PMID 31995682
96. Pibarot P, Salaun E, Dahou A, et al. Echocardiographic Results of Transcatheter Versus Surgical Aortic Valve Replacement in Low-Risk Patients: The PARTNER 3 Trial. *Circulation.* May 12 2020; 141(19): 1527-1537. PMID 32272848
97. Shahim B, Malaisrie SC, George I, et al. Postoperative Atrial Fibrillation or Flutter Following Transcatheter or Surgical Aortic Valve Replacement: PARTNER 3 Trial. *JACC Cardiovasc Interv.* Jul 26 2021; 14(14): 1565-1574. PMID 34294398
98. Aedma SK, Khan N, Altamimi A, et al. Umbrella Meta-analysis Evaluating the Effectiveness of ViV-TAVI vs Redo SAVR. *SN Compr Clin Med.* Feb 26 2022; 4(63). DOI: 10.1007/s42399-022-01136-x.
99. Raschpichler M, de Waha S, Holzhey D, et al. Valve-in-Valve Transcatheter Aortic Valve Replacement Versus Redo Surgical Aortic Valve Replacement for Failed Surgical Aortic Bioprostheses: A Systematic Review and Meta-Analysis. *J Am Heart Assoc.* Dec 20 2022; 11(24): e7965. PMID 36533610
100. Sá MP, Van den Eynde J, Simonato M, et al. Late outcomes of valve-in-valve transcatheter aortic valve implantation versus re-replacement: Meta-analysis of reconstructed time-to-event data. *Int J Cardiol.* Jan 01 2023; 370: 112-121. PMID 36370873
101. National Institute For Health And Care Excellence (NICE). Interventional procedure overview of valve-in-valve TAVI for aortic bioprosthetic valve dysfunction [IPG653]. June 2019. <https://www.nice.org.uk/guidance/ipg653/evidence/overview-final-pdf-6834685357>. Accessed March 8, 2024.
102. Phan K, Zhao DF, Wang N, et al. Transcatheter valve-in-valve implantation versus reoperative conventional aortic valve replacement: a systematic review. *J Thorac Dis.* Jan 2016; 8(1): E83-93. PMID 26904259
103. Chen HL, Liu K. Clinical outcomes for transcatheter valve-in-valve in treating surgical bioprosthetic dysfunction: A meta-analysis. *Int J Cardiol.* Jun 01 2016; 212: 138-41. PMID 27038719
104. Tam DY, Vo TX, Wijeyesundera HC, et al. Transcatheter valve-in-valve versus redo surgical aortic valve replacement for the treatment of degenerated bioprosthetic aortic valve: A systematic review and meta-analysis. *Catheter Cardiovasc Interv.* Dec 01 2018; 92(7): 1404-1411. PMID 30024102



105. Webb JG, Murdoch DJ, Alu MC, et al. 3-Year Outcomes After Valve-in-Valve Transcatheter Aortic Valve Replacement for Degenerated Bioprostheses: The PARTNER 2 Registry. *J Am Coll Cardiol*. Jun 04 2019; 73(21): 2647-2655. PMID 31146808
106. Hahn RT, Webb J, Pibarot P, et al. 5-Year Follow-Up From the PARTNER 2 Aortic Valve-in-Valve Registry for Degenerated Aortic Surgical Bioprostheses. *JACC Cardiovasc Interv*. Apr 11 2022; 15(7): 698-708. PMID 35393102
107. Hirji SA, Percy ED, Zogg CK, et al. Comparison of in-hospital outcomes and readmissions for valve-in-valve transcatheter aortic valve replacement vs. reoperative surgical aortic valve replacement: a contemporary assessment of real-world outcomes. *Eur Heart J*. Aug 01 2020; 41(29): 2747-2755. PMID 32445575
108. Kaneko T, Makkar RR, Krishnaswami A, et al. Valve-in-Surgical-Valve With SAPIEN 3 for Transcatheter Aortic Valve Replacement Based on Society of Thoracic Surgeons Predicted Risk of Mortality. *Circ Cardiovasc Interv*. May 2021; 14(5): e010288. PMID 34003666
109. Tam DY, Dharma C, Rocha RV, et al. Transcatheter ViV Versus Redo Surgical AVR for the Management of Failed Biological Prosthesis: Early and Late Outcomes in a Propensity-Matched Cohort. *JACC Cardiovasc Interv*. Mar 23 2020; 13(6): 765-774. PMID 31954671
110. van Steenberg GJ, van Straten B, Lam KY, et al. Report on outcomes of valve-in-valve transcatheter aortic valve implantation and redo surgical aortic valve replacement in the Netherlands. *Neth Heart J*. Feb 2022; 30(2): 106-112. PMID 34373997
111. Begun X, Butt JH, Kristensen SL, et al. Patient characteristics and long-term outcomes in patients undergoing transcatheter aortic valve implantation in a failed surgical prosthesis vs in a native valve: A Danish nationwide study. *Am Heart J*. Oct 2023; 264: 183-189. PMID 37178995
112. Zahid S, Ullah W, Zia Khan M, et al. Cerebral Embolic Protection during Transcatheter Aortic Valve Implantation: Updated Systematic Review and Meta-Analysis. *Curr Probl Cardiol*. Jun 2023; 48(6): 101127. PMID 35124076
113. Haussig S, Mangner N, Dwyer MG, et al. Effect of a Cerebral Protection Device on Brain Lesions Following Transcatheter Aortic Valve Implantation in Patients With Severe Aortic Stenosis: The CLEAN-TAVI Randomized Clinical Trial. *JAMA*. Aug 09 2016; 316(6): 592-601. PMID 27532914
114. Van Mieghem NM, van Gils L, Ahmad H, et al. Filter-based cerebral embolic protection with transcatheter aortic valve implantation: the randomised MISTRAL-C trial. *EuroIntervention*. Jul 20 2016; 12(4): 499-507. PMID 27436602
115. Kapadia SR, Kodali S, Makkar R, et al. Protection Against Cerebral Embolism During Transcatheter Aortic Valve Replacement. *J Am Coll Cardiol*. Jan 31 2017; 69(4): 367-377. PMID 27815101
116. Kapadia SR, Makkar R, Leon M, et al. Cerebral Embolic Protection during Transcatheter Aortic-Valve Replacement. *N Engl J Med*. Oct 06 2022; 387(14): 1253-1263. PMID 36121045
117. Nishimura RA, Otto CM, Bonow RO, et al. 2014 AHA/ACC guideline for the management of patients with valvular heart disease: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. *J Am Coll Cardiol*. Jun 10 2014; 63(22): 2438-88. PMID 24603192
118. Nishimura RA, O'Gara PT, Bonow RO. Guidelines Update on Indications for Transcatheter Aortic Valve Replacement. *JAMA Cardiol*. Sep 01 2017; 2(9): 1036-1037. PMID 28768333
119. Otto CM, Nishimura RA, Bonow RO, et al. 2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. *J Am Coll Cardiol*. Feb 02 2021; 77(4): e25-e197. PMID 33342586
120. National Institute For Health And Care Excellence (NICE). Valve-in-valve TAVI for aortic bioprosthetic valve dysfunction (Interventional procedures guidance [IPG653]). June 2019. <https://www.nice.org.uk/guidance/ipg653>. Accessed March 8, 2024.
121. National Institute For Health And Care Excellence (NICE). Heart valve disease presenting in adults: investigation and management [NG208]. November 2021. <https://www.nice.org.uk/guidance/ng208/chapter/Recommendations#interventions>. Accessed March 8, 2024.



122. Centers for Medicare and Medicaid Services (CMS). Decision Memo for Transcatheter Aortic Valve Replacement (TAVR) (CAG-00430R). <https://www.cms.gov/medicare-coverage-database/details/nca-decision-memo.aspx?NCAId=293>. Accessed March 8, 2024.

## History

Date	Comments
02/27/12	New Policy – Add to Surgery section. Policy created with literature search through October 2011; considered medically necessary for patients who are not surgical candidates; investigational for all other indications.
09/27/12	Update Coding Section – ICD-10 codes are now effective 10/01/2014.
02/11/13	Replace policy. Policy updated with literature review, references 7, 15, 16, 18, 20, 23-28, 30 added. Medically necessary indications added for patients who are at high risk for open surgery using the transfemoral approach, and patients who are at high risk for open surgery using the transapical approach. Investigational statement added for treatment of degenerated bio-prosthetic valve or failed TAVI (Valve-in-Valve approach), and for vascular approaches other than transfemoral or transapical. Codes updated.
12/23/13	Coding Update. Add new CPT 33366, effective 01/01/14; 0318T discontinued effective 12/31/13; deleted codes 0256T – 0259T removed.
02/10/14	Replace policy. Policy updated with literature review through November 15, 2013. References 8, 18, 19, 22, 23, 27 added. Policy statement revised to include medically necessary indication for TAVI by the transapical approach for patients who are not suitable candidates for open surgery. ICD-10 Procedure codes 35.05 and 35.22 removed from the policy; they were provided for informational purposes only.
12/17/14	Annual Review. Policy statement revised to remove statement that “procedures performed via the transaxillary, transiliac, transaortic, or other approaches” are investigational, to reflect the approval of the CoreValve device that is labeled for use via transaxillary, transfemoral, and transaortic approaches. Policy statement added stating that devices should be used according to their FDA approved indication. Clinical input supported proposed policy statements. Policy updated with literature review through September 1, 2014, and the results of clinical input. References 9-10, 15-17, 23, 28-34, 36, 41-43, 45, 47, 49-52, 57-59 added; others renumbered/removed. Policy statements changed as noted. ICD-9 and ICD-10 diagnosis and procedure codes removed; these do not relate to policy adjudication.
12/08/15	Annual Review. Policy reviewed. No new references added. Policy statements unchanged.
02/01/16	Coding update. Added 93799.



Date	Comments
11/01/16	Annual Review, changes approved October 11, 2016. Medically necessary policy statement added for valve-in-valve implantation in patients at high or prohibitive risk for open surgery. Policy updated with literature review through December 9, 2015, references added. Policy statement added as noted. Coding update, removed unlisted CPT code 93799.
05/01/17	Annual Review, changes approved April 11, 2017. Policy updated with literature review through December 22, 2016; references 20, 31-34, 45, 48-55, and 85 added. Policy statements unchanged.
10/24/17	Policy moved to new format; no change to policy statements.
07/01/18	Annual Review, approved June 22, 2018. Policy updated with literature review through February 2018; references 19, 26, 37, 42-50, 58-60, 68, and 82-83 added. Policy statements changed to add patients at intermediate surgical risk to first medically necessary statement.
04/01/19	Minor update, added Documentation Requirements section.
05/01/19	Annual Review, approved April 2, 2019. Policy updated with literature review through February 2019; references 73-76 added. Policy statements unchanged.
04/01/20	Delete policy, approved March 10, 2020. This policy will be deleted effective July 2, 2020, and replaced with InterQual criteria for dates of service on or after July 2, 2020. Policy updated with literature review through November 2019; references added. Medically Necessary policy statement related to patients with native valve aortic stenosis changed to add an exclusion for patients with unicuspid or bicuspid aortic valve and to add an inclusion for patients at low risk for open surgery, Policy statement changes are effective April 1, 2020.
07/02/20	Delete policy.
11/01/20	Policy reinstated effective February 5, 2021, approved October 13, 2020. Policy statements unchanged.
05/01/21	Annual Review, approved April 1, 2021. Policy updated with literature review through January 9, 2021; references added. Policy statements unchanged.
01/01/22	New policy approved December 14, 2021. This policy replaces 7.01.132 Transcatheter Aortic-Valve Implantation for Aortic Stenosis. This is effectively a policy renumber. Added policy statement that use of a cerebral embolic protection device during TAVR procedures is considered investigational. CPT code 33370 added. HCPCS code C1884 added.
05/01/22	Annual Review, approved April 11, 2022. Policy updated with literature review through December 29, 2021; references added. Policy statements unchanged.
05/01/23	Policy renumbered to 7.01.132 Transcatheter Aortic-Valve Implantation for Aortic Stenosis from 7.01.585, approved April 11, 2023. Policy updated with literature review through January 3, 2023; references added. Minor editorial refinements to existing policy statements; intent unchanged. Changed the wording from "patient" to



Date	Comments
	"individual" throughout the policy for standardization. Removed effective date from CPT code 33370.
05/01/24	Annual Review, approved April 9, 2024. Policy updated with literature review through January 8, 2024; references added. Policy statements refined based on review of clinical input. For TAVI and ViV TAVI, the criterion of left ventricular ejection fraction greater than 20% was removed. A statement was added for consideration of individuals who may be at high risk of open surgery but not demonstrated on Society of Thoracic Surgeons risk score, 'Individual is considered at increased surgical risk for an open surgery (e.g., repeat sternotomy) due to a history of congenital vascular anomalies AND/OR has a complex intrathoracic surgical history, as documented by at least 2 cardiovascular specialists (including a cardiac surgeon)'.

**Disclaimer:** This medical policy is a guide in evaluating the medical necessity of a particular service or treatment. The Company adopts policies after careful review of published peer-reviewed scientific literature, national guidelines and local standards of practice. Since medical technology is constantly changing, the Company reserves the right to review and update policies as appropriate. Member contracts differ in their benefits. Always consult the member benefit booklet or contact a member service representative to determine coverage for a specific medical service or supply. CPT codes, descriptions and materials are copyrighted by the American Medical Association (AMA). ©2024 Premera All Rights Reserved.

**Scope:** Medical policies are systematically developed guidelines that serve as a resource for Company staff when determining coverage for specific medical procedures, drugs or devices. Coverage for medical services is subject to the limits and conditions of the member benefit plan. Members and their providers should consult the member benefit booklet or contact a customer service representative to determine whether there are any benefit limitations applicable to this service or supply. This medical policy does not apply to Medicare Advantage.







### Discrimination is Against the Law

LifeWise Health Plan of Washington (LifeWise) complies with applicable Federal and Washington state civil rights laws and does not discriminate on the basis of race, color, national origin, age, disability, sex, gender identity, or sexual orientation. LifeWise does not exclude people or treat them differently because of race, color, national origin, age, disability, sex, gender identity, or sexual orientation. LifeWise provides free aids and services to people with disabilities to communicate effectively with us, such as qualified sign language interpreters and written information in other formats (large print, audio, accessible electronic formats, other formats). LifeWise provides free language services to people whose primary language is not English, such as qualified interpreters and information written in other languages. If you need these services, contact the Civil Rights Coordinator. If you believe that LifeWise has failed to provide these services or discriminated in another way on the basis of race, color, national origin, age, disability, sex, gender identity, or sexual orientation, you can file a grievance with: Civil Rights Coordinator — Complaints and Appeals, PO Box 91102, Seattle, WA 98111, Toll free: 855-332-6396, Fax: 425-918-5592, TTY: 711, Email [AppealsDepartmentInquiries@LifeWiseHealth.com](mailto:AppealsDepartmentInquiries@LifeWiseHealth.com). You can file a grievance in person or by mail, fax, or email. If you need help filing a grievance, the Civil Rights Coordinator is available to help you. You can also file a civil rights complaint with the U.S. Department of Health and Human Services, Office for Civil Rights, electronically through the Office for Civil Rights Complaint Portal, available at <https://ocrportal.hhs.gov/ocr/portal/lobby.jsf>, or by mail or phone at: U.S. Department of Health and Human Services, 200 Independence Ave SW, Room 509F, HHH Building, Washington, D.C. 20201, 1-800-368-1019, 800-537-7697 (TDD). Complaint forms are available at <http://www.hhs.gov/ocr/office/file/index.html>. You can also file a civil rights complaint with the Washington State Office of the Insurance Commissioner, electronically through the Office of the Insurance Commissioner Complaint Portal available at <https://www.insurance.wa.gov/file-complaint-or-check-your-complaint-status>, or by phone at 800-562-6900, 360-586-0241 (TDD). Complaint forms are available at <https://fortress.wa.gov/oic/onlineservices/cc/pub/complaintinformation.aspx>.

### Language Assistance

**ATENCIÓN:** si habla español, tiene a su disposición servicios gratuitos de asistencia lingüística. Llame al 800-817-3056 (TTY: 711).

**注意:** 如果您使用繁體中文，您可以免費獲得語言援助服務。請致電 800-817-3056 (TTY: 711)。

**CHÚ Ý:** Nếu bạn nói Tiếng Việt, có các dịch vụ hỗ trợ ngôn ngữ miễn phí dành cho bạn. Gọi số 800-817-3056 (TTY: 711).

**주의:** 한국어를 사용하시는 경우, 언어 지원 서비스를 무료로 이용하실 수 있습니다. 800-817-3056 (TTY: 711) 번으로 전화해 주십시오.

**ВНИМАНИЕ:** Если вы говорите на русском языке, то вам доступны бесплатные услуги перевода. Звоните 800-817-3056 (телетайп: 711).

**PAUNAWA:** Kung nagsasalita ka ng Tagalog, maaari kang gumamit ng mga serbisyo ng tulong sa wika nang walang bayad. Tumawag sa 800-817-3056 (TTY: 711).

**УВАГА!** Якщо ви розмовляєте українською мовою, ви можете звернутися до безкоштовної служби мовної підтримки.

Телефонуйте за номером 800-817-3056 (телетайп: 711).

**ប្រយ័ត្ន:** បើសិនជាអ្នកនិយាយ ភាសាខ្មែរ, សេវាជំនួយផ្នែកភាសា ដោយមិនគិតលុយ គឺអាចមានសំរាប់អ្នក។ ចូរ ទូរស័ព្ទ 800-817-3056 (TTY: 711)។

**注意事項:** 日本語を話される場合、無料の言語支援をご利用いただけます。800-817-3056 (TTY:711) まで、お電話にてご連絡ください。

**ማስታወሻ:** የሚናገሩት ቋንቋ አማርኛ ከሆነ የትርጉም እርዳታ ድርጅቶች፣ በነጻ ሊያገለግሉት ተዘጋጅተዋል። ወደ ሚከተለው ቁጥር ይደውሉ 800-817-3056 (መስማት ለተሳናቸው፡ 711)።

**XIYYEEFFANNA:** Afaan dubbattu Oroomiffa, tajaajila gargaarsa afaanii, kanfaltiidhaan ala, ni argama. Bilbilaa 800-817-3056 (TTY: 711).

**ملحوظة:** إذا كنت تتحدث اذكر اللغة، فإن خدمات المساعدة اللغوية تتوافر لك بالمجان. اتصل برقم 800-817-3056 (رقم هاتف الصم والبكم: 711).

**ਧਿਆਨ ਦਿਓ:** ਜੇ ਤੁਸੀਂ ਪੰਜਾਬੀ ਬੋਲਦੇ ਹੋ, ਤਾਂ ਭਾਸ਼ਾ ਵਿੱਚ ਸਹਾਇਤਾ ਸੇਵਾ ਤੁਹਾਡੇ ਲਈ ਮੁਫਤ ਉਪਲਬਧ ਹੈ। 800-817-3056 (TTY: 711) 'ਤੇ ਕਾਲ ਕਰੋ।

**ACHTUNG:** Wenn Sie Deutsch sprechen, stehen Ihnen kostenlos sprachliche Hilfsdienstleistungen zur Verfügung. Rufnummer: 800-817-3056 (TTY: 711).

**ໂປດອຸບ:** ຖ້າວ່າ ທ່ານເວົ້າພາສາ ລາວ, ການບໍລິການຊ່ວຍເຫຼືອດ້ານພາສາ, ໂດຍບໍ່ຄ່າສ່ຽງຄ່າ, ຄວນມີພ້ອມໃຫ້ທ່ານ. ໂທ 800-817-3056 (TTY: 711).

**ATANSYON:** Si w pale Kreyòl Ayisyen, gen sévis èd pou lang ki disponib gratis pou ou. Rele 800-817-3056 (TTY: 711).

**ATTENTION:** Si vous parlez français, des services d'aide linguistique vous sont proposés gratuitement. Appelez le 800-817-3056 (ATS : 711).

**UWAGA:** Jeżeli mówisz po polsku, możesz skorzystać z bezpłatnej pomocy językowej. Zadzwoń pod numer 800-817-3056 (TTY: 711).

**ATENÇÃO:** Se fala português, encontram-se disponíveis serviços linguísticos, grátis. Ligue para 800-817-3056 (TTY: 711).

**ATTENZIONE:** In caso la lingua parlata sia l'italiano, sono disponibili servizi di assistenza linguistica gratuiti. Chiamare il numero 800-817-3056 (TTY: 711).

**توجہ:** اگر بہ زبان فارسی گفتگو می کنید، تسهیلات زبانی بصورت رایگان برای شما فراهم می باشد. با 800-817-3056 (TTY: 711) تماس بگیرید.